Figure 1.
Anti-B-CLL reactivity of anti-third-party CTLs. On day 2 or 3 following bone marrow transplantation (BMT) from a SCID donor, chimeric mice were infused intraperitoneally with 100 to 150 × 106 PBMCs from patients with B-CLL (A,B,E,F) or AML (C,D). On days 4 to 10, some of the leukemia recipients were infused intraperitoneally with 10 × 106 to 15 × 106 allogeneic (B,D) or autologous (F) CTLs. One week later, peritoneal lavages from each individual mouse were tested for the presence of B-CLL or AML cells by FACS analysis. A representative experiment is shown. Numbers in graphs represent percent of cells in the upper-right quadrant (double positive cells).
